CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
Fludeoxyglucose F-18 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03824535
NCT03824535Phase 2Completed
CompareCT.gov

18F-FSPG PET/CT and Integrated Biomarkers for Early Lung Cancer Detection in Patients With Indeterminate Pulmonary Nodules

Andrei Iagaru·interventional·Posted Jan 31, 2019·Updated Apr 9, 2025

In Brief

A Phase 2 clinical trial evaluating Computed Tomography, Fludeoxyglucose F-18, and 2 other interventions for Cigarette Smoker and 4 related conditions. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This phase II trial studies how well 18F-FSPG positron emission tomography (PET)/computed tomography (CT) work in diagnosing early lung cancer in patients with indeterminate lung nodules. PET imaging with an imaging agent called 18F-FDG is often used in combination with a PET/CT scanner to evaluate cancers. Giving 18F-FSPG before a PET/CT scan may work better in helping researchers diagnose early lung cancer in patients with lung nodules.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCigarette Smoker, Current Smoker, Former Smoker, Multiple Pulmonary Nodules, Pulmonary Nodule
CountriesUnited States
CollaboratorsCanary Foundation, Boston University, United States Department of Defense

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedJan 31, 2019
Enrollment StartFeb 4, 2019
Primary CompletionJul 30, 2021
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 7.4 years ago

Interventions

Computed Tomographyother

Undergo PET/CT

Fludeoxyglucose F-18drug

Given IV

Fluorine F 18 L-glutamate Derivative BAY94-9392drug

Given IV

Positron Emission Tomography (PET/CT)other

Undergo PET/CT